Leukocyte (e.g., Lymphocyte, Granulocyte, Monocyte, Etc.) Patents (Class 435/7.24)
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140341939Abstract: The present invention provides a tumor antigen-specific Th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using same.Type: ApplicationFiled: December 14, 2012Publication date: November 20, 2014Inventor: Keiko Udaka
-
Patent number: 8889367Abstract: This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject.Type: GrantFiled: September 14, 2011Date of Patent: November 18, 2014Assignee: New York UniversityInventors: Mukundan Attur, Steven B. Abramson
-
Publication number: 20140335098Abstract: Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described.Type: ApplicationFiled: January 2, 2013Publication date: November 13, 2014Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa Macagno
-
Publication number: 20140336078Abstract: This invention discloses devices and methods for high throughput skin sensitization detection. The devices comprise a microfabricated chamber comprising a region having one or more input channels and an outlet, and a face suitable for mounting a skin tissue and in fluidic communication with the region. The devices can be used in the methods for determining a prognosis of sensitization in an animal subject and identifying compounds that do not cause sensitization and thus are suitable for preparing cosmetic compositions.Type: ApplicationFiled: August 10, 2012Publication date: November 13, 2014Applicant: Rutgers, The State University of New JerseyInventors: Tim Maguire, Martin L. Yarmush, Rene S. Schloss, Bhaskar Mitra, Rohit Jindal, Mehdi Ghodbane
-
Publication number: 20140335542Abstract: The disclosed invention includes methods and kits for the removal of white blood cells from samples of enriched rare cells.Type: ApplicationFiled: March 14, 2014Publication date: November 13, 2014Inventors: Galla Chandra Rao, Brad Foulk, Denis Smirnov
-
Patent number: 8883491Abstract: The present invention generally relates to systems and methods for counting biomolecules or cells. In certain embodiments, the invention provides a cell counting or biomolecule counting system including: a covered chamber having a known height and configured to hold a suspension of biomolecules or cells in a sample; at least one fluorescent light source connected to at least one fluorescent light beam narrowing device; a bright-field light source connected to a bright-field light beam narrowing device; a microscope objective; a detection device; a fluorescent filter assembly to allow only excitation light to illuminate the sample and allow only emission light from the sample to be imaged by the detection device; and a movable light shutter to block bright-field light during fluorescent detection.Type: GrantFiled: April 8, 2009Date of Patent: November 11, 2014Assignee: Nexcelom Bioscience LLCInventors: Bo Lin, Peter Y. Li, Jean Qiu, Timothy Smith, Todd Sobolewski, Alnoor Pirani
-
Publication number: 20140328764Abstract: The development of fluorescent bioprobes comprising organic fluorescent compounds that exhibit aggregation induced emission (AIE) properties, methods of producing the same, and their practical applications for in vitro and in vivo bioimaging.Type: ApplicationFiled: September 3, 2012Publication date: November 6, 2014Applicants: NATIONAL UNIVERSITY OF SINGAPORE, THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Benzhong Tang, Wei Qin, Jianzhao Liu, Sijie Chen, Tsz Kin Kwok, Bin Liu, Kai Li, Dan Ding, Haibin Shi, Jun Long Geng, Jingzhi Sun, Anjun Qin, Qiuli Zhao
-
Publication number: 20140328852Abstract: The invention relates to an immunogenic peptide of eight amino acids that is generated naturally in the intestine of celiac patients by means of the hydrolysis of ingested gluten. In addition, the invention relates to the use of the peptide, or antibodies generated against same, for the in vitro monitoring and/or diagnosis of celiac disease, as well as to the use of such antibodies for the detection of gluten in food. The invention further relates to the use of the aforementioned peptide as a therapeutic target for the development of compounds or compositions for use in the diagnosis, treatment and/or prevention of this pathological condition, as well as to the use of the peptide and the antibodies against same for the prevention and/or treatment of celiac disease.Type: ApplicationFiled: September 28, 2012Publication date: November 6, 2014Inventors: David Bernardo Ordiz, Jose Antonio Garrote Adrados, Alfredo Ramon Blanco Quiros, Eduardo Arranz Sanz, Angel Cebolla Ramirez
-
Publication number: 20140329809Abstract: A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea.Type: ApplicationFiled: October 26, 2012Publication date: November 6, 2014Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Isabelle Carlavan, Martin Steinhoff
-
Publication number: 20140329249Abstract: A method of individually releasing from an entity one or more members of a sub-group of biological units included in a heterogeneous group of biological units is provided. The method includes binding the group of biological units including the sub-group of biological units to the entity via a linker. Following binding, the location of the one or more members on the entity is determined. Once the location is determined, a localized physical pulse is applied to the one or more members. The localized physical pulse individually releases the one or more members from the entity by dissociating the linker.Type: ApplicationFiled: April 25, 2014Publication date: November 6, 2014Applicant: Roche Molecular Systems, Inc.Inventors: Judith Brand-Meier, Claudio Cherubini, Andreas Drechsler, Nicole Gwerder, Martin Kopp, Edwin Oosterbroek, Emad Sarofim
-
Publication number: 20140328763Abstract: The present invention relates to nanoparticle compositions and treatment of cardiovascular disease using nanoparticles to target Class A and B scavenger receptors. This invention further relates to methods of detecting cells that express scavenger receptors, detecting atherosclerotic lesions, and targeting bioactive amphiphilic macromolecules to cells that express scavenger receptors.Type: ApplicationFiled: August 8, 2012Publication date: November 6, 2014Applicants: THE TRUSTEES OF PRINCETON UNIVERSITY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Adam W. York, Prabhas V. Moghe, Kathryn E. Uhrich, Robert Prud'homme
-
Publication number: 20140315735Abstract: Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence.Type: ApplicationFiled: February 20, 2014Publication date: October 23, 2014Applicant: International Institute of Cancer Immunology, Inc.Inventor: Haruo SUGIYAMA
-
Patent number: 8865420Abstract: The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.Type: GrantFiled: May 22, 2008Date of Patent: October 21, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Omar D. Perez, Garry P. Nolan, Jonathan M. Irish
-
Patent number: 8865479Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 16, 2010Date of Patent: October 21, 2014Assignee: President and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Publication number: 20140308209Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: November 15, 2012Publication date: October 16, 2014Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Publication number: 20140302530Abstract: This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products.Type: ApplicationFiled: February 12, 2014Publication date: October 9, 2014Applicant: OREGON HEALTH AND SCIENCE UNIVERSITYInventors: Louis Picker, Klaus Frueh, Scott G. Hansen, Collin Powers
-
Publication number: 20140296091Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.Type: ApplicationFiled: February 21, 2014Publication date: October 2, 2014Inventors: Hans Martin Vordermeier, Benjamin Sidders, Neil Graham Stoker, Katie Ewer
-
Publication number: 20140294849Abstract: The invention provides a TLR agonist and an antibody which binds to an antigen such as a ?-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before the antibody or after the antibody. The compositions and methods provided are useful for prevention or treatment of Alzheimer's disease.Type: ApplicationFiled: January 5, 2012Publication date: October 2, 2014Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Daniel Larocque, Remi Palmantier, Pascale Tribout-Jover
-
Patent number: 8846322Abstract: Provided are a method and kit for isolating a target cell by using particles comprising polymers having positive charge and negative charge and at least one antibody bound to polymers. The target cell in the biological sample may be efficiently isolated and detected by using a method and kit according to an exemplary embodiment.Type: GrantFiled: March 7, 2011Date of Patent: September 30, 2014Assignee: Samsung Electronics Co., Ltd.Inventors: Jong-myeon Park, Jeong-gun Lee
-
Publication number: 20140287437Abstract: An apparatus, system, and method for magnetic separation of cells are disclosed. By combining inkjet printing technology and magnetic labeling of cells, accurate cell counts are obtained using an optical microscope. Mouse CD4+ lymphocytes are attached to micron sized magnetic beads and printed through a modified, commercial inkjet printer. The labeled cells are then attached to a glass slide covering a permanent magnet. Cell counts can be obtained by use of regular and inverted optical microscopes and imaging software. The magnetically-labeled beads are collected for evaluation on a modified polymer coupon that is placed in front of a permanent magnet and the unlabeled cells fall into an excess container. Flow cytometry results verify the presence of the CD4+ protein on the LBRM-33 lymphocytes membrane. Protein-specific attachment of magnetic microspheres to the lymphocytes is utilized for sorting CD4+ lymphocytes.Type: ApplicationFiled: March 22, 2013Publication date: September 25, 2014Inventors: Thomas Boland, Sylvia L. Natividad, Julio Rincon
-
Publication number: 20140286962Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.Type: ApplicationFiled: March 19, 2014Publication date: September 25, 2014Applicant: ALEXION PHARMACEUTICALS, INC.Inventors: Mayur MOVALIA, Andrea ILLINGWORTH, Susan FAAS MCKNIGHT, Russell P. ROTHER
-
Publication number: 20140287438Abstract: A method for determining the efficacy of a vaccine comprising: providing serum from an animal inoculated with a vaccine; providing a plurality of antigen-linked nanoparticles; contacting the serum with the plurality of antigen linked nanoparticles; contacting the serum and the plurality of antigen linked nanoparticles with a plurality of Fc receptor-expressing cells; measuring amount antigen-linked nanoparticle uptake by of the Fc receptor-expressing cells; determining efficacy of the vaccine by comparing the level of antigen-linked nanoparticle uptake to a baseline level of uptake wherein a greater nanoparticle uptake compared to the baseline level of uptake is indicative of greater vaccine efficacy.Type: ApplicationFiled: March 15, 2014Publication date: September 25, 2014Applicant: South Dakota Board of RegentsInventors: Victor Huber, Grigoriy Sereda, James Dale
-
Publication number: 20140287952Abstract: Methods of identifying antigen-specific antibody-secreting and antibody-forming cells, such as antigen-specific B cells, and methods for cloning the antigen-specific antibody sequences of the antibody produced by these cells are provided. In particular, the methods include enriching B cells for antigen-specific B cells, culturing the antigen-specific B cells to generate clonal B cell populations, detecting clonal B cells that produce a single antigen-specific antibody, optionally screening the clonal B cell populations for functional activity, staining and sorting the cells to isolate the antigen-specific B cells, sequencing the nucleic acids encoding the antigen-specific antibody sequences, expressing the sequences to produce an antibody, isolating the antibody and screening the antibody for antigen recognition. The methods provide improved enrichment and selection of antigen-specific antibody-secreting and antibody-forming cells, which enhances recovery of antigen-specific antibodies.Type: ApplicationFiled: March 18, 2014Publication date: September 25, 2014Applicant: ALDERBIO HOLDINGS LLCInventors: DANIEL S. ALLISON, JENS BILLGREN, ANNE ELISABETH CARVALHO JENSEN, BENJAMIN H. DUTZAR, LEON F. GARCIA-MARTINEZ, KATIE ANDERSON, ETHAN WAYNE OJALA, JOHN A. LATHAM
-
Patent number: 8840899Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.Type: GrantFiled: August 5, 2009Date of Patent: September 23, 2014Assignee: Emory UniversityInventors: Rafi Ahmed, Christian P. Larsen, Koichi Araki
-
Publication number: 20140273018Abstract: A method for quantitatively measuring white blood cell (leukocyte) count and/or white blood cell (leukocyte) subsets count involves adding specific antibodies labeled with a marker to the biological fluid sample, capture of white blood cells from a fluid sample by a retainer, removal of other than leukocyte cells and other interfering substances by washing or using specific magnetic beads, and reading the result. The device for use in the present method includes a retainer for leukocyte cells and an absorption pad for taking up all excess washing solution flowing past the sample.Type: ApplicationFiled: April 16, 2013Publication date: September 18, 2014Applicant: Allied Innovative Systems, LLCInventors: Simon Bystryak, Rasa Santockyte
-
Publication number: 20140274925Abstract: Disclosed herein are compositions and methods for diagnosing, treating, and monitoring Lyme disease.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Chenggang Jin, Gottfried H. Kellermann
-
Publication number: 20140272945Abstract: Disclosed herein are a method for manufacturing a multi-functional bio-material conjugate used as a biosensor for detecting microorganisms, and the like, and a multi-functional bio-material conjugate manufactured by means of the same. The method for manufacturing a multi-functional bio-material conjugate includes: (a) coating a first nanoparticle having magnetic or fluorescent characteristics with protein; (b) manufacturing a conjugate by adsorbing a second nanoparticle having metallic characteristics onto the first nanoparticle coated with protein; and (c) manufacturing the multi-functional bio-material conjugate by adsorbing a bio-material onto the conjugate. The method for manufacturing a multi-functional bio-material conjugate according to the present invention may prevent precipitation of the nanoparticles, easily immobilize the bio-material, and manufacture a bio-material conjugate having multiple functions, by using two kinds of the particles.Type: ApplicationFiled: October 12, 2012Publication date: September 18, 2014Inventors: Min-Gon Kim, Yun Ju Sung, Ju Young Byun, Young-Kyoung Oh, Hyou-Arm Joung
-
Publication number: 20140273019Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.Type: ApplicationFiled: February 13, 2014Publication date: September 18, 2014Applicant: Biogen Idec MA Inc.Inventors: Yen-Ming Hsu, Susan Kalled
-
Publication number: 20140271619Abstract: Described herein are methods of screening for compounds that bind to conformational isomers of CD20 polypeptides. Also described are antibodies that bind to conformational isomers of CD20 polypeptides.Type: ApplicationFiled: March 12, 2013Publication date: September 18, 2014Inventor: Ross Stewart Chambers
-
Patent number: 8835188Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: September 16, 2014Assignee: Presidents and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Patent number: 8835187Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.Type: GrantFiled: August 6, 2013Date of Patent: September 16, 2014Assignee: Presidents and Fellows of Harvard CollegeInventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
-
Publication number: 20140255393Abstract: Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (SCNP), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.Type: ApplicationFiled: February 28, 2014Publication date: September 11, 2014Applicant: Nodality, Inc.Inventors: Jason Ptacek, Rachael Hawtin, Erik Evensen, James Cordeiro, Alessandra Cesano
-
Publication number: 20140255389Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: May 29, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Patent number: 8828737Abstract: Methods for using focused light scattering techniques for the optical sensing of biological particles suspended in a liquid medium are disclosed. The optical sensing enables one to characterize particles size and/or distribution in a given sample. This, in turn, allows one to identify the biological particles, determine their relative particle density, detect particle shedding, and identify particle aggregation. The methods are also useful in screening and optimizing drug candidates, evaluating the efficacy and dosage levels of such drugs, and in personalized medicine applications.Type: GrantFiled: July 14, 2009Date of Patent: September 9, 2014Assignee: Invitrox, Inc.Inventor: Don Gabriel
-
Patent number: 8828671Abstract: Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.Type: GrantFiled: February 5, 2013Date of Patent: September 9, 2014Assignee: Laboratory Corporation of America HoldingsInventors: Norman B. Purvis, Gregory T. Stelzer
-
Publication number: 20140248281Abstract: Methods of determining the erythroid prognosis of an anemia, methods of treating a blood disorder in a subject comprising an anemia, and methods of treating a blood disorder in a subject comprising an expanded erythron are all provided.Type: ApplicationFiled: February 25, 2014Publication date: September 4, 2014Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventors: Andrew Chow, Paul S. Frenette, Miriam Merad
-
Publication number: 20140249044Abstract: The invention relates to cell-based methods for diversifying, expressing and selecting binding molecules, e.g., antibodies, and target molecules to which they bind, all of which are expressed in the same cell. The target molecule can be a member of a ligand binding pair comprising a cell-surface expressed ligand binding receptor molecule and its cognate ligand, which interact within the cell. The methods provide retaining either the antibody or its target in a cell organelle as the site of binding and interaction. By performance of the methods, the binding or non-binding of the antibody to its target molecule within the cell produces a cell phenotype that is detectable at the cell surface via high throughput assays, e.g., flow cytometry. The methods are particularly useful for generating, recovering and providing antibodies that have optimal target molecule binding properties or activities for potential therapeutic use. Methods for generating diversity in such antibodies are also provided.Type: ApplicationFiled: February 28, 2014Publication date: September 4, 2014Applicant: Technophage, Investigaçâo E Desenvolvimento Em Biotecnologia, SAInventors: João Manuel Braz Gonçalves, Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Soraia Rafaela Santiago de Oliveira
-
Publication number: 20140242077Abstract: Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also provided are nucleic acids, expression vectors and host cells encoding the multispecific binding proteins.Type: ApplicationFiled: January 23, 2014Publication date: August 28, 2014Applicant: AbbVie, Inc.Inventors: Chee-Ho CHOI, Qingfeng TAO, Philip BARDWELL, Tariq GHAYUR
-
Publication number: 20140242612Abstract: A system and method for analyzing a biomarker in a biological sample is provided. A biological sample is loaded onto a microchip and an enzyme-linked immunosorbent assay specific to the biomarker is performed on the microchip. A color image of the microchip is generated using a mobile device and a color intensity of a selected portion of the color image is determined. The color intensity is correlated with a biomarker concentration using a baseline curve calculation and the concentration of the biomarker is then reported.Type: ApplicationFiled: July 16, 2012Publication date: August 28, 2014Inventors: Shuqi Wang, Utkan Demirci, Bin Ye, Ragip Akbas
-
Publication number: 20140243235Abstract: Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject.Type: ApplicationFiled: April 8, 2014Publication date: August 28, 2014Inventors: Norman Latov, Susanne Renaud
-
Patent number: 8815526Abstract: An affinity ligand is reactive to the GARP protein may be capable of binding to an extracellular domain of GARP protein expressed on regulatory T (Treg) cells. The affinity ligand may be an antibody and may be used to identify Treg cells. A method comprises providing a blood sample from a subject and determining the amount of Treg cells in that sample. A composition containing Treg cells may be administered to an individual to suppress effector T cell activity in the individual. A composition containing an affinity ligand capable of binding to a GARP domain may be administered to an individual to suppress Treg cell activity and increase effector T cell activity in the individual. A kit for detecting Treg cells may include an affinity ligand reactive with mammalian GARP protein.Type: GrantFiled: March 31, 2006Date of Patent: August 26, 2014Assignee: Case Western Reserve UniversityInventors: Edina Garaczi, Hideaki Sugiyama, Rolland Gyulai, Kevin D. Cooper, Thomas S. McCormick
-
Patent number: 8815527Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.Type: GrantFiled: April 26, 2011Date of Patent: August 26, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Omar D. Perez, Garry P. Nolan
-
Publication number: 20140235475Abstract: A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.Type: ApplicationFiled: June 25, 2012Publication date: August 21, 2014Inventor: Isabelle Carlavan
-
Publication number: 20140234297Abstract: The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more FcRs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region.Type: ApplicationFiled: September 24, 2013Publication date: August 21, 2014Inventor: Genevieve HANSEN
-
Publication number: 20140227272Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.Type: ApplicationFiled: February 8, 2014Publication date: August 14, 2014Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
-
Publication number: 20140227283Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.Type: ApplicationFiled: June 22, 2012Publication date: August 14, 2014Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Regional du Cancer de Montpellier-Val d'Aurelle, UNIVERSITE DE MONTPELLIER 1, OriBase PharmaInventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
-
Patent number: 8802384Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.Type: GrantFiled: March 9, 2010Date of Patent: August 12, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Tokuzo Arao, Kanae Kudo, Kazuhiko Nakagawa, Kazuto Nishio
-
Publication number: 20140220014Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease.Type: ApplicationFiled: February 28, 2014Publication date: August 7, 2014Applicants: University of Washington, ZymoGenetics, Inc.Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
-
Publication number: 20140220600Abstract: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.Type: ApplicationFiled: March 7, 2014Publication date: August 7, 2014Applicant: Rutgers, The State University of New JerseyInventor: Maria L. Gennaro